Copyright
©The Author(s) 2017.
World J Gastroenterol. Jul 21, 2017; 23(27): 4856-4866
Published online Jul 21, 2017. doi: 10.3748/wjg.v23.i27.4856
Published online Jul 21, 2017. doi: 10.3748/wjg.v23.i27.4856
Imatinib[23] | Sunitinib[25] | Regorafenib[28] | |
KIT mutation | |||
Exon 11 | OR 63% | CB 34% | Increased sensitivity |
Exon 9 | OR 37%. Intermediate sensitivity. Higher dose 800 mg more effective in metastatic disease than 400 mg daily | CB 34% | Unknown |
Exon 13 | OR 40%. Sensitivity as primary mutation. Resistance as secondary mutation | CB 100% | Unknown |
Exon 14 | Resistance as secondary mutation | Unknown | Unknown |
Exon 17 | OR 25%. Primary mutation sensitive in vitro. Resistance as secondary mutation | CB 0% | Unknown |
PDGFRA mutation | |||
Exon 18 | OR 50% | CB 0% | Unknown |
Exon 12 | Increased sensitivity | CB 0% | Unknown |
Exon 14 | Increased sensitivity in vitro | Unknown | Unknown |
Exon 18 D842V | Decreased sensitivity | Decreased sensitivity | Unknown |
BRAF mutation | Resistance | Resistance | Unknown |
SDH mutation | Decreased sensitivity | Unknown | Increased sensitivity |
No KIT, PDGFRA or BRAF mutation | OR 28% | CB 56% | Some activity |
- Citation: Lim KT, Tan KY. Current research and treatment for gastrointestinal stromal tumors. World J Gastroenterol 2017; 23(27): 4856-4866
- URL: https://www.wjgnet.com/1007-9327/full/v23/i27/4856.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i27.4856